{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:08:35Z","timestamp":1793304515687,"version":"4.5.0"},"reference-count":13,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2023,2,1]]},"abstract":"Importance<\/jats:title>Predictors consistently associated with psychosis liability and course of illness in schizophrenia (SCZ) spectrum disorders (SSD), including the need for clozapine treatment, are lacking. Longitudinally ascertained medication use may empower studies examining associations between polygenic risk scores (PRSs) and pharmacotherapy choices.<\/jats:p><\/jats:sec>Objective<\/jats:title>To examine associations between PRS-SCZ loading and groups with different liabilities to SSD (individuals with SSD taking clozapine, individuals with SSD taking other antipsychotics, their parents and siblings, and unrelated healthy controls) and between PRS-SCZ and the likelihood of receiving a prescription of clozapine relative to other antipsychotics.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This genetic association study was a multicenter, observational cohort study with 6 years of follow-up. Included were individuals diagnosed with SSD who were taking clozapine or other antipsychotics, their parents and siblings, and unrelated healthy controls. Data were collected from 2004 until 2021 and analyzed between October 2021 and September 2022.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Polygenic risk scores for SCZ.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Multinomial logistic regression was used to examine possible differences between groups by computing risk ratios (RRs), ie, ratios of the probability of pertaining to a particular group divided by the probability of healthy control status. We also computed PRS-informed odd ratios (ORs) for clozapine use relative to other antipsychotics.<\/jats:p><\/jats:sec>Results<\/jats:title>Polygenic risk scores for SCZ were generated for 2344 participants (mean [SD] age, 36.95 years [14.38]; 994 female individuals [42.4%]) who remained after quality control screening (557 individuals with SSD taking clozapine, 350 individuals with SSD taking other antipsychotics during the 6-year follow-up, 542 parents and 574 siblings of individuals with SSD, and 321 unrelated healthy controls). All RRs were significantly different from 1; RRs were highest for individuals with SSD taking clozapine (RR, 3.24; 95% CI, 2.76-3.81; P<\/jats:italic>\u2009=\u20092.47\u2009\u00d7\u200910\u221246<\/jats:sup>), followed by individuals with SSD taking other antipsychotics (RR, 2.30; 95% CI, 1.95-2.72; P<\/jats:italic>\u2009=\u20093.77\u2009\u00d7\u200910\u221222<\/jats:sup>), parents (RR, 1.44; 95% CI, 1.25-1.68; P<\/jats:italic>\u2009=\u20091.76\u2009\u00d7\u200910\u22126<\/jats:sup>), and siblings (RR, 1.40; 95% CI, 1.21-1.63; P<\/jats:italic>\u2009=\u20098.22\u2009\u00d7\u200910\u22126<\/jats:sup>). Polygenic risk scores for SCZ were positively associated with clozapine vs other antipsychotic use (OR, 1.41; 95% CI, 1.22-1.63; P<\/jats:italic>\u2009=\u20092.98\u2009\u00d7\u200910\u22126<\/jats:sup>), suggesting a higher likelihood of clozapine prescriptions among individuals with higher PRS-SCZ.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this study, PRS-SCZ loading differed between groups of individuals with SSD, their relatives, and unrelated healthy controls, with patients taking clozapine at the far end of PRS-SCZ loading. Additionally, PRS-SCZ was associated with a higher likelihood of clozapine prescribing. Our findings may inform early intervention and prognostic studies of the value of using PRS-SCZ to personalize antipsychotic treatment.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2022.4234","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T16:07:48Z","timestamp":1671638868000},"page":"181","source":"Crossref","is-referenced-by-count":22,"title":["Associations Between Polygenic Risk Score Loading, Psychosis Liability, and Clozapine Use Among Individuals With Schizophrenia"],"prefix":"10.1001","volume":"80","author":[{"given":"Bochao D.","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Neuropsychology, Maastricht University Medical Center, Maastricht, the Netherlands"},{"name":"Research Institute Brainclinics, Brainclinics Foundation, Nijmegen, the Netherlands"},{"name":"Department of Preventive Medicine, Institute of Biomedical Informatics, Bioinformatics Center, School of Basic Medical Sciences, Henan University, Kaifeng, China"},{"name":"Department of Psychiatry, University Medical Center Utrecht, Utrecht University, Brain Center Rudolf Magnus, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justo","family":"Pinz\u00f3n-Espinosa","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University Medical Center Utrecht, Utrecht University, Brain Center Rudolf Magnus, Utrecht, the Netherlands"},{"name":"Sant Pau Mental Health Group, Institut d\u2019Investigaci\u00f3 Biom\u00e8dica Sant Pau (IBB-Sant Pau), Hospital de la Santa Creu i Sant Pau, Universitat Aut\u00f2noma de Barcelona (UAB), Barcelona, Catalonia, Spain"},{"name":"Department of Medicine, School of Medicine, University of Barcelona, Barcelona, Spain"},{"name":"Department of Clinical Psychiatry, School of Medicine, University of Panama, Panama City, Panama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Blouzard","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University Medical Center Utrecht, Utrecht University, Brain Center Rudolf Magnus, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marte Z.","family":"van der Horst","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University Medical Center Utrecht, Utrecht University, Brain Center Rudolf Magnus, Utrecht, the Netherlands"},{"name":"GGNet Mental Health, Warnsveld, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Okhuijsen-Pfeifer","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University Medical Center Utrecht, Utrecht University, Brain Center Rudolf Magnus, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristel R.","family":"van Eijk","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University Medical Center Utrecht, Utrecht University, Brain Center Rudolf Magnus, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinan","family":"Guloksuz","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neuropsychology, Maastricht University Medical Center, Maastricht, the Netherlands"},{"name":"Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter J.","family":"Peyrot","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Amsterdam UMC, Amsterdam, the Netherlands"},{"name":"Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, VU University Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurjen J.","family":"Luykx","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neuropsychology, Maastricht University Medical Center, Maastricht, the Netherlands"},{"name":"Research Institute Brainclinics, Brainclinics Foundation, Nijmegen, the Netherlands"},{"name":"Department of Psychiatry, University Medical Center Utrecht, Utrecht University, Brain Center Rudolf Magnus, Utrecht, the Netherlands"},{"name":"GGNet Mental Health, Warnsveld, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alkomiet","family":"Hasan","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Wagner","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Pantelis","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian P.","family":"Everall","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Ayhan","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. O.","family":"Babao\u011flu","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Bak","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter","family":"Alink","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Beld","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Bouhuis","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Edlinger","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I .M.","family":"Erdo\u011fan","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Gutwinski","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tero","family":"Hallikainen","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Jeger-land","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markku","family":"L\u00e4hteenvuo","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariken B.","family":"de Koning","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Morgenroth","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"M\u00fcderriso\u011flu","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Oviedo-Salcedo","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Schreiter","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eila","family":"Repo-Tiihonen","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heli","family":"Tuppurainen","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Veereschild","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selene R.T.","family":"Veerman","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"de Vos","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Cohen","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan P.A.M.","family":"Bogers","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.E.","family":"An\u0131l Ya\u011fc\u0131o\u011flu","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jari","family":"Tiihonen","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Ripke","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad A.","family":"Bousman","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Van Beek","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Okhuijsen-Pfeifer","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marte","family":"van der Horst","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristel","family":"van Eijk","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ertu\u011frul","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Yoca","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"G\u00f6rlitz","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.P.","family":"Grootens","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Narang","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Schneider-Thoma","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9 S.","family":"Kahn","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwin","family":"Bekema","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Kleymann","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurjen J.","family":"Luykx","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behrooz Z.","family":"Alizadeh","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese","family":"van Amelsvoort","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiepke","family":"Cahn","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieuwe","family":"de Haan","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederike","family":"Schirmbeck","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia J.P.","family":"Simons","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"van Os","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Rutten","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruud","family":"van Winkel","sequence":"additional","affiliation":[{"name":"for the Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7906","key":"ybr220007r1","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/s41586-022-04434-5","article-title":"Mapping genomic loci implicates genes and synaptic biology in schizophrenia.","volume":"604","author":"Trubetskoy","year":"2022","journal-title":"Nature"},{"issue":"7256","key":"ybr220007r2","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/nature08185","article-title":"Common polygenic variation contributes to risk of schizophrenia and bipolar disorder.","volume":"460","author":"Purcell","year":"2009","journal-title":"Nature"},{"issue":"9","key":"ybr220007r3","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.biopsych.2021.04.018","article-title":"A comparison of ten polygenic score methods for psychiatric disorders applied across multiple cohorts.","volume":"90","author":"Ni","year":"2021","journal-title":"Biol Psychiatry"},{"issue":"6","key":"ybr220007r4","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1038\/s41380-020-0689-5","article-title":"Association of polygenic score for major depression with response to lithium in patients with bipolar disorder.","volume":"26","author":"Amare","year":"2021","journal-title":"Mol Psychiatry"},{"issue":"2","key":"ybr220007r5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.biopsych.2019.10.015","article-title":"The genetics of the mood disorder spectrum: genome-wide association analyses of more than 185,000 cases and 439,000 controls.","volume":"88","author":"Coleman","year":"2020","journal-title":"Biol Psychiatry"},{"issue":"3","key":"ybr220007r6","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1001\/jamapsychiatry.2021.3799","article-title":"Interaction testing and polygenic risk scoring to estimate the association of common genetic variants with treatment resistance in schizophrenia.","volume":"79","author":"Pardi\u00f1as","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"ybr220007r7","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1093\/schbul\/sbx007","article-title":"Polygenic risk score for schizophrenia and treatment-resistant schizophrenia.","volume":"43","author":"Wimberley","year":"2017","journal-title":"Schizophr Bull"},{"issue":"3","key":"ybr220007r8","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.rpsm.2020.05.003","article-title":"Clozapine in patients with schizoaffective disorder: a systematic review.","volume":"14","author":"Rey Souto","year":"2021","journal-title":"Rev Psiquiatr Salud Ment (Engl Ed)"},{"issue":"1","key":"ybr220007r9","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2020.140","article-title":"Phenome-wide and genome-wide analyses of quality of life in schizophrenia.","volume":"7","author":"Pazoki","year":"2020","journal-title":"BJPsych Open"},{"issue":"1","key":"ybr220007r10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41398-022-01884-3","article-title":"Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders.","volume":"12","author":"Okhuijsen-Pfeifer","year":"2022","journal-title":"Transl Psychiatry"},{"issue":"1","key":"ybr220007r11","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1038\/s41467-019-09718-5","article-title":"Polygenic prediction via Bayesian regression and continuous shrinkage priors.","volume":"10","author":"Ge","year":"2019","journal-title":"Nat Commun"},{"issue":"12","key":"ybr220007r12","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S2215-0366(21)00253-4","article-title":"Post-partum psychosis and its association with bipolar disorder in the UK: a case-control study using polygenic risk scores.","volume":"8","author":"Di Florio","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"ybr220007r13","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-21706-2","volume-title":"Modern Applied Statistics with S","author":"Venables","year":"2002","edition":"4th ed"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2799589\/jamapsychiatry_lin_2022_br_220007_1675180172.93819.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T16:32:34Z","timestamp":1675269154000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2799589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.4234","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,1]]}}}